Please ensure Javascript is enabled for purposes of website accessibility

Coronavirus Antibody Test From Abbott Receives Emergency Use Authorization

By Cory Renauer – May 11, 2020 at 2:10PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The company plans to ship 90 million of the laboratory-run blood tests for SARS-CoV-2 antibodies by the end of June.

The FDA on Monday authorized the use of a new antibody test that can determine who has been exposed to the coronavirus that has claimed the lives of at least 74,270 Americans to date. Wide deployment of Abbott's (ABT -1.50%) freshly authorized SARS-CoV-2 antibody test could help people safely return to some semblance of normal life sooner rather than later.

By the end of May, Abbott plans to ship 30 million new antibody tests worldwide, followed by 60 million more in June. As a global leader in the diagnostic space, Abbott probably won't have trouble hitting that target. 

Laboratory technicians placing sample tubes in an Olympus rack.

Image source: Getty Images.

How much is enough?

In places where governments and health systems have been able to test the population widely and perform contact tracing -- Taiwan, South Korea, Hong Kong, New Zealand, and Australia among them -- life returned to a semblance of normalcy weeks ago without any new uncontained breakouts to date. Sadly, the availability of such COVID-19 tests in the U.S. is as yet far from where it needs to be.

The COVID Tracking Project has counted almost 9 million tests run in the U.S. to date. That may sound like a lot, but it doesn't tell us how much demand to expect for Abbott's new antibody test. To know if enough people are being tested to spot new outbreaks and hotspots before they spread out of control, public health officials need to see the percentage of positive tests fall to the low single-digit percentage range.

During the week ended May 2, the CDC reported the percentage of tests returning positive results from public health and commercial laboratories fell to 13.2%. That's far too high to safely allow life to return to normal, but it's significantly lower than it was the previous week.

Cory Renauer has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Abbott Laboratories Stock Quote
Abbott Laboratories
$98.34 (-1.50%) $-1.50

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 09/27/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.